| IL-33–Dependent Type 2 Inflammation during Rhinovirus-induced Asthma Exacerbations In Vivo DJ Jackson, H Makrinioti, BMJ Rana, BWH Shamji, MB Trujillo-Torralbo, ... American journal of respiratory and critical care medicine 190 (12), 1373-1382, 2014 | 622 | 2014 |
| The role of viruses in acute exacerbations of asthma DJ Jackson, SL Johnston Journal of Allergy and Clinical Immunology 125 (6), 1178-1187, 2010 | 458 | 2010 |
| Asthma exacerbations: origin, effect, and prevention DJ Jackson, A Sykes, P Mallia, SL Johnston Journal of Allergy and Clinical Immunology 128 (6), 1165-1174, 2011 | 457 | 2011 |
| Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation J Beale, A Jayaraman, DJ Jackson, JDR Macintyre, MR Edwards, ... Science translational medicine 6 (256), 256ra134-256ra134, 2014 | 363 | 2014 |
| Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation M Toussaint, DJ Jackson, D Swieboda, A Guedán, TD Tsourouktsoglou, ... Nature medicine 23 (6), 681-691, 2017 | 299 | 2017 |
| Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness MR Edwards, K Strong, A Cameron, RP Walton, DJ Jackson, SL Johnston Journal of Allergy and Clinical Immunology 140 (4), 909-920, 2017 | 227 | 2017 |
| Characterization of severe asthma worldwide: data from the International Severe Asthma Registry E Wang, ME Wechsler, TN Tran, LG Heaney, RC Jones, AN Menzies-Gow, ... Chest 157 (4), 790-804, 2020 | 223 | 2020 |
| Real-world effectiveness of benralizumab in severe eosinophilic asthma JE Kavanagh, AP Hearn, J Dhariwal, G d’Ancona, A Douiri, C Roxas, ... Chest 159 (2), 496-506, 2021 | 200 | 2021 |
| Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort LG Heaney, LP de Llano, M Al-Ahmad, V Backer, J Busby, GW Canonica, ... Chest 160 (3), 814-830, 2021 | 156 | 2021 |
| Real-world effectiveness and the characteristics of a “super-responder” to mepolizumab in severe eosinophilic asthma JE Kavanagh, G d’Ancona, M Elstad, L Green, M Fernandes, L Thomson, ... Chest 158 (2), 491-500, 2020 | 151 | 2020 |
| Eosinophils in health and disease: a state-of-the-art review ME Wechsler, A Munitz, SJ Ackerman, MG Drake, DJ Jackson, ... Mayo Clinic Proceedings 96 (10), 2694-2707, 2021 | 147 | 2021 |
| A comprehensive evaluation of nasal and bronchial cytokines and chemokines following experimental rhinovirus infection in allergic asthma: increased interferons (IFN-γ and IFN … TT Hansel, T Tunstall, MB Trujillo-Torralbo, B Shamji, A Del-Rosario, ... EBioMedicine 19, 128-138, 2017 | 121 | 2017 |
| Azithromycin for acute exacerbations of asthma: the AZALEA randomized clinical trial SL Johnston, M Szigeti, M Cross, C Brightling, R Chaudhuri, T Harrison, ... JAMA internal medicine 176 (11), 1630-1637, 2016 | 120 | 2016 |
| Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era DJ Jackson, J Busby, PE Pfeffer, A Menzies-Gow, T Brown, R Gore, ... Thorax 76 (3), 220-227, 2021 | 108 | 2021 |
| Pathogenesis of viral infection in exacerbations of airway disease AI Ritchie, HA Farne, A Singanayagam, DJ Jackson, P Mallia, ... Annals of the American Thoracic Society 12 (Supplement 2), S115-S132, 2015 | 106 | 2015 |
| Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label … A Menzies-Gow, M Gurnell, LG Heaney, J Corren, EH Bel, J Maspero, ... The Lancet Respiratory Medicine 10 (1), 47-58, 2022 | 104 | 2022 |
| Over-and under-diagnosis in asthma J Kavanagh, DJ Jackson, BD Kent Breathe 15 (1), e20-e27, 2019 | 102 | 2019 |
| Defining a severe asthma super-responder: findings from a Delphi process JW Upham, C Le Lievre, DJ Jackson, M Masoli, ME Wechsler, DB Price, ... The Journal of Allergy and Clinical Immunology: In Practice 9 (11), 3997-4004, 2021 | 95 | 2021 |
| Composite type-2 biomarker strategy versus a symptom–risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel … LG Heaney, J Busby, CE Hanratty, R Djukanovic, A Woodcock, ... The Lancet Respiratory Medicine 9 (1), 57-68, 2021 | 93 | 2021 |
| Mucosal type 2 innate lymphoid cells are a key component of the allergic response to aeroallergens J Dhariwal, A Cameron, MB Trujillo-Torralbo, A Del Rosario, ... American journal of respiratory and critical care medicine 195 (12), 1586-1596, 2017 | 86 | 2017 |
Sebastian L JohnstonProfessor of Respiratory Medicine & Allergy, Imperial College LondonVerified email at imperial.ac.uk
